BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23602555)

  • 1. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.
    Li P; Luo Y; Chen YM
    Heart Lung Circ; 2013 Oct; 22(10):852-60. PubMed ID: 23602555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
    Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
    Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
    Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
    Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
    Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
    Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
    Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.
    Savarese G; Trimarco B; Dellegrottaglie S; Prastaro M; Gambardella F; Rengo G; Leosco D; Perrone-Filardi P
    PLoS One; 2013; 8(3):e58287. PubMed ID: 23472172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
    De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.
    Karlström P; Alehagen U; Boman K; Dahlström U;
    Eur J Heart Fail; 2011 Oct; 13(10):1096-103. PubMed ID: 21715446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
    Auerbach SR; Richmond ME; Lamour JM; Blume ED; Addonizio LJ; Shaddy RE; Mahony L; Pahl E; Hsu DT
    Circ Heart Fail; 2010 Sep; 3(5):606-11. PubMed ID: 20573993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
    Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
    J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
    Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
    J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
    Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
    Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study.
    Boldanova T; Noveanu M; Breidthardt T; Potocki M; Reichlin T; Taegtmeyer A; Christ M; Laule K; Stelzig C; Mueller C
    Int J Cardiol; 2010 Jul; 142(3):265-72. PubMed ID: 19185372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge.
    Hogenhuis J; Voors AA; Jaarsma T; Hillege HL; Hoes AW; van Veldhuisen DJ
    Am Heart J; 2006 May; 151(5):1012.e1-5. PubMed ID: 16644323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responder to BNP-guided treatment in heart failure. The process of defining a responder.
    Karlström P; Dahlström U; Boman K; Alehagen U
    Scand Cardiovasc J; 2015; 49(6):316-24. PubMed ID: 26153427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-type natriuretic peptide. Guided vs. conventional care in outpatients with chronic heart failure: a retrospective study.
    De Vecchis R; Esposito C; Di Biase G; Ariano C
    Minerva Cardioangiol; 2013 Aug; 61(4):437-49. PubMed ID: 23846010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide.
    Miller WL; Burnett JC; Hartman KA; Henle MP; Burritt MF; Jaffe AS
    Am J Cardiol; 2005 Sep; 96(6):837-41. PubMed ID: 16169373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.